-
Something wrong with this record ?
Chimerism as an important marker in post-transplant monitoring chimerism monitoring
H. Cechova, M. Leontovycova, L. Pavlatova,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
30362266
DOI
10.1111/tan.13407
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Adult MeSH
- Genetic Testing methods MeSH
- Hematologic Neoplasms genetics immunology mortality therapy MeSH
- Transplantation, Homologous MeSH
- Immune Tolerance * MeSH
- Cohort Studies MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Myeloablative Agonists therapeutic use MeSH
- Graft vs Host Disease diagnosis genetics immunology mortality MeSH
- Graft Survival * MeSH
- Transplantation Conditioning methods MeSH
- Recurrence MeSH
- Graft Rejection diagnosis genetics immunology mortality MeSH
- Risk Factors MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Tandem Repeat Sequences MeSH
- Histocompatibility Testing MeSH
- Hematopoietic Stem Cell Transplantation * MeSH
- Transplantation Chimera genetics immunology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Cell chimerism determination is important for the monitoring of engraftment dynamics and for relapse prediction. Our cohort of 474 patients was divided into two groups according to the determination methods used over time, and by their chimerism status. A significant difference in survival was observed between mixed vs complete chimerism (P < 0.0001 vs P < 0.0002) in both patient groups, and also vs microchimerism (P = 0.0201) in the second group. Detection of mixed chimerism is thus a high-risk factor, and microchimerism is potentially a risk factor in the post-transplantation course. Methods with a high sensitivity for monitoring cell chimerism significantly improve the assessment of patients post-transplant, and they enable the identification of patients with high relapse risk. Supported by MH CZ-DRO (00023736, UHKT).
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034941
- 003
- CZ-PrNML
- 005
- 20191014101219.0
- 007
- ta
- 008
- 191007s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/tan.13407 $2 doi
- 035 __
- $a (PubMed)30362266
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cechova, Hana $u HLA department, The Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic.
- 245 10
- $a Chimerism as an important marker in post-transplant monitoring chimerism monitoring / $c H. Cechova, M. Leontovycova, L. Pavlatova,
- 520 9_
- $a Cell chimerism determination is important for the monitoring of engraftment dynamics and for relapse prediction. Our cohort of 474 patients was divided into two groups according to the determination methods used over time, and by their chimerism status. A significant difference in survival was observed between mixed vs complete chimerism (P < 0.0001 vs P < 0.0002) in both patient groups, and also vs microchimerism (P = 0.0201) in the second group. Detection of mixed chimerism is thus a high-risk factor, and microchimerism is potentially a risk factor in the post-transplantation course. Methods with a high sensitivity for monitoring cell chimerism significantly improve the assessment of patients post-transplant, and they enable the identification of patients with high relapse risk. Supported by MH CZ-DRO (00023736, UHKT).
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a genetické testování $x metody $7 D005820
- 650 _2
- $a rejekce štěpu $x diagnóza $x genetika $x imunologie $x mortalita $7 D006084
- 650 12
- $a přežívání štěpu $7 D006085
- 650 _2
- $a nemoc štěpu proti hostiteli $x diagnóza $x genetika $x imunologie $x mortalita $7 D006086
- 650 _2
- $a hematologické nádory $x genetika $x imunologie $x mortalita $x terapie $7 D019337
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a testování histokompatibility $7 D006650
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a imunologická tolerance $7 D007108
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myeloablativní agonisté $x terapeutické užití $7 D019653
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a tandemové repetitivní sekvence $7 D020080
- 650 _2
- $a transplantační chiméra $x genetika $x imunologie $7 D018183
- 650 _2
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 _2
- $a homologní transplantace $7 D014184
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Leontovycova, Monika $u HLA department, The Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic.
- 700 1_
- $a Pavlatova, Lucie $u HLA department, The Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic.
- 773 0_
- $w MED00195031 $t HLA $x 2059-2310 $g Roč. 92 Suppl 2, č. - (2018), s. 60-63
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30362266 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191014101643 $b ABA008
- 999 __
- $a ok $b bmc $g 1451601 $s 1073491
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 92 Suppl 2 $c - $d 60-63 $e - $i 2059-2310 $m HLA $n HLA $x MED00195031
- LZP __
- $a Pubmed-20191007
